MANAGEMENT OF ADULT ACUTE MYELOGENOUS LEUKEMIA
MANAGEMENT OF ADULT ACUTE MYELOGENOUS LEUKEMIA
复制标题
DOI：
10.1136/bmj.1.5846.131
复制
发表时间：
1973-01-01
影响因子：
105.7
通讯作者：
SCOTT, RB
中科院分区：
文献类型：
--
作者：
CROWTHER, D;POWLES, RL;SCOTT, RB
患有急性髓性白血病的连续性成人患者在圣巴塞洛缪医院接受了由柔红霉素和阿糖胞苷组成的缓解诱导药物治疗。72例患者采用间歇性5天疗程，39例患者（54%）获得完全缓解。22例患者的替代药物治疗方案导致较少的缓解，但这可能是由于两组的年龄差异。年龄和初始血小板计数是决定缓解诱导治疗成功的重要因素;年龄较大和血小板计数低的患者反应较差。一系列23例达到缓解的患者被分为两组;一组接受间歇性联合化疗作为唯一的维持形式，另一组在化疗的基础上每周给予免疫治疗。免疫治疗包括照射的同种异体白血病细胞和B.C.G.仅接受化疗的10名患者中有8名已经复发，而免疫治疗组13名患者中有5名复发。希望随着更多患者进入维持试验，这种形式的维持治疗的这些有希望的初步结果将得到证实。
Consecutive adult patients admitted to St. Bartholomew's Hospital with acute myelogenous leukaemia have been treated with a remission induction drug schedule consisting of daunorubicin and cytosine arabinoside. Intermittent five-day courses were used in 72 patients, and a complete remission was obtained in 39 patients (54%). An alternative drug schedule in 22 patients resulted in fewer remissions but this may have been due to age differences in the two groups. Age and initial platelet count were found to be important factors in determining the success of remission induction therapy; the older patients and those with low platelet counts responded less well.A series of 23 patients who achieved remissions was divided into two groups; one received intermittent combination chemotherapy as the only form of maintenance, and the other was given weekly immunotherapy in addition to the chemotherapy. The immunotherapy consisted of irradiated allogeneic leukaemic cells and B.C.G. Eight of the 10 patients on chemotherapy alone have already relapsed compared with five out of 13 patients in the immunotherapy group. It is hoped that these promising initial results with this form of maintenance will be confirmed as more patients enter the maintenance trials.